Trevi Therapeutics Inc (NASDAQ:TRVI)’s traded shares stood at 0.76 million during the last session, with the company’s beta value hitting 0.94. At the close of trading, the stock’s price was $4.27, to imply an increase of 1.43% or $0.06 in intraday trading. The TRVI share’s 52-week high remains $4.68, putting it -9.6% down since that peak but still an impressive 70.26% since price per share fell to its 52-week low of $1.27. The company has a valuation of $381.59M, with an average of 7.9 million shares in intraday trading volume over the past 10 days and average of 1.68 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Trevi Therapeutics Inc (TRVI), translating to a mean rating of 1.10. Of 3 analyst(s) looking at the stock, 0 analyst(s) give TRVI a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.12.
Trevi Therapeutics Inc (NASDAQ:TRVI) trade information
After registering a 1.43% upside in the last session, Trevi Therapeutics Inc (TRVI) has traded red over the past five days. The 5-day price performance for the stock is 2.89%, and 48.26% over 30 days. With these gigs, the year-to-date price performance is 218.66%. Short interest in Trevi Therapeutics Inc (NASDAQ:TRVI) saw shorts transact 1.41 million shares and set a 2.76 days time to cover.
The extremes give us $6 and $6 for target low and target high price respectively. As such, TRVI has been trading -40.52% off suggested target high and -40.52% from its likely low.
Trevi Therapeutics Inc (TRVI) estimates and forecasts
Looking at statistics comparing Trevi Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Trevi Therapeutics Inc (TRVI) shares are 43.29% up over the last 6 months, with its year-to-date growth rate lower than industry average at -68.97% against 16.60%.
TRVI Dividends
Trevi Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Trevi Therapeutics Inc (NASDAQ:TRVI)’s Major holders
Trevi Therapeutics Inc insiders hold 1.03% of total outstanding shares, with institutional holders owning 70.43% of the shares at 71.16% float percentage. In total, 70.43% institutions holds shares in the company, led by NEA MANAGEMENT COMPANY, LLC. As of 2024-06-30, the company held over 11.37 million shares (or 11.4255% of shares), all amounting to roughly $33.88 million.
The next major institution holding the largest number of shares is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with 7.38 million shares, or about 7.4169% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $22.0 million.
